{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Hematopoietic+Stem+Cell+Transplantation&page=60",
    "query": {
      "intervention": "Allogeneic Hematopoietic Stem Cell Transplantation",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 2012,
    "total_pages": 202,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Hematopoietic+Stem+Cell+Transplantation&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+Hematopoietic+Stem+Cell+Transplantation&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T04:55:14.099Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03761914",
      "title": "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Triple-negative Breast Cancer",
        "Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "galinpepimut-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide",
          "type": "OTHER"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sellas Life Sciences Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-09-30",
      "completion_date": "2022-10-27",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Whittier, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761914"
    },
    {
      "nct_id": "NCT06180863",
      "title": "Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "oral azacitidine (CC-486)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-11",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06180863"
    },
    {
      "nct_id": "NCT02251821",
      "title": "JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2014-10-20",
      "completion_date": "2026-01-22",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02251821"
    },
    {
      "nct_id": "NCT04930055",
      "title": "Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "COVID-19 Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2206,
      "start_date": "2021-06-30",
      "completion_date": "2022-03-08",
      "has_results": false,
      "last_update_posted_date": "2023-05-19",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 2,
      "location_summary": "Carmel, Indiana • Indianapolis, Indiana",
      "locations": [
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04930055"
    },
    {
      "nct_id": "NCT06991114",
      "title": "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Rheumatoid Arthritis (RA)",
        "Idiopathic Inflammatory Myopathies (IIMs)",
        "Systemic Sclerosis (SSc)",
        "Rheumatoid Arthritis (RA",
        "IIM",
        "Myositis",
        "Scleroderma",
        "Sjogren Syndrome",
        "Sjogrens Disease"
      ],
      "interventions": [
        {
          "name": "Allogeneic NK Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-07-09",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 31,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06991114"
    },
    {
      "nct_id": "NCT00104858",
      "title": "Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Prolymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Small Lymphocytic Lymphoma",
        "T-Cell Large Granular Lymphocyte Leukemia"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2004-12",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Seattle, Washington",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104858"
    },
    {
      "nct_id": "NCT04328714",
      "title": "Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edwin Horwitz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-12-02",
      "completion_date": "2022-07-20",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04328714"
    },
    {
      "nct_id": "NCT02677064",
      "title": "Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Leukemia",
        "Newly Diagnosed",
        "Relapsed"
      ],
      "interventions": [
        {
          "name": "assessments",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1365,
      "start_date": "2016-02",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 3,
      "location_summary": "Hartford, Connecticut • New York, New York • Allentown, Pennsylvania",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Allentown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02677064"
    },
    {
      "nct_id": "NCT03712878",
      "title": "2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Donor Lymphocyte Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2018-09-19",
      "completion_date": "2025-03-19",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712878"
    },
    {
      "nct_id": "NCT02423915",
      "title": "Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Fucosylated Regulatory T Cells",
          "type": "PROCEDURE"
        },
        {
          "name": "Cord Blood Infusions",
          "type": "PROCEDURE"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Non-Fucosylated Regulatory T Cells",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2015-07-30",
      "completion_date": "2020-10-06",
      "has_results": false,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-10-25T04:55:14.099Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423915"
    }
  ]
}